Overview
Munich, January 21, 2025 – With a team led by Holger Ebersberger and Thomas Diekmann, McDermott Will & Emery advised NORD Holding on the acquisition of HKS health solutions GmbH (HKS). McDermott also advised on the financing of the acquisition, with the Private Equity Finance team led by Matthias Weissinger.
The acquisition of HKS is part of the formation of 1Q Health Group, which – following the acquisition of ABJ alive GmbH in 2024 – continues NORD Holding’s European buy-and-build strategy in the market for high-quality dietary supplements and pharmaceuticals. The HKS founders, Benjamin Hawlik, Markus Koisser and Dirk Sachon, will reinvest and remain active as management board members.
HKS, created in 2021 through the merger of three specialized companies, is active in the areas of contract manufacturing of high-quality dietary supplements and pharmaceuticals, trading in more than 1,500 raw materials, and distribution of private labels under the umbrella brand HAWLIK.
NORD Holding is a private equity and asset management company with assets under management of around EUR 4 billion. The focus of NORD Holding’s direct business is on the structuring and financing of corporate succession models, the acquisition of parts of groups/subsidiaries and the expansion financing of medium-sized companies. The fund investment division focuses on the micro and small cap segment of medium-sized European private equity funds.
McDermott advised NORD Holding already on the acquisition of ABJ alive.
The McDermott team was led by Holger Ebersberger, Thomas Diekmann, and Matthias Weissinger, and included Julia Külzer, Parsin Walsi, Alexandra Prato, Franziska Sauer, Tim Becker, Florian Schiefer, Carina Kant, Jana Grieb, Christian Lebrecht, Lea Hachmeister, Christian Rolf, Janek Joosten, Steffen Woitz, Claus Färber, Ettore Scandale, and Emma Greselin.
